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The Korea Biobank Project (KBP) was led by the Ministry of Health and Welfare to
establish a network between the National Biobank of Korea and biobanks run by
university-affiliated general hospitals (regional biobanks). The Ministry of Health
and Welfare started the project to enhance medical and health technology by
collecting, managing, and providing researchers with high-quality human bio-
resources. The National Biobank of Korea, under the leadership of the Ministry of
Health and Welfare, collects specimens through various cohorts and regional
biobanks within university hospitals gather specimens from patients. The project
began in 2008, and the first phase ended in 2012, which meant that there needed
to be a plan for the second phase that begins in 2013. Consequently, profes-
sionals from within and outside the project were gathered to develop a plan for
the second phase. Under the leadership of the planning committee, six working
groups were formed to formulate a practical plan. By conducting two workshops
with experts in the six working groups and the planning committee and three
forums in 2011 and 2012, they have developed a strategic plan for the second
phase of the KBP. This document presents a brief report of the second phase of
the project based on a discussion with them.
During the first phase of the project (2008e2012), a network was set up between
the National Biobank of Korea and 17 biobanks at university-affiliated hospitals in
an effort to unify informatics and governance among the participating biobanks.
The biobanks within the network manage data on their biospecimens with
a unified Biobank Information Management System. Continuous efforts are being
made to develop a common standard operating procedure for resource collec-
tion, management, distribution, and personal information security, and
currently, management of these data is carried out in a somewhat unified
manner. In addition, the KBP has trained and educated professionals to work
within the biobanks, and has also carried out various publicity promotions to the
public and researchers. During the first phase, biospecimens from more thanted under the terms of the Creative Commons Attribution Non-Commercial License (http://
0) which permits unrestricted non-commercial use, distribution, and reproduction in any
roperly cited.
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200,000 patients from hospitals were collected, which were distributed to
approximately 600 research projects.
The planning committee for the second phase evaluated that the first phase of
the KBP was successful. However, the first phase of the project was meant to
allow autonomy to the individual biobanks. The biobanks were able to choose the
kind of specimens they were going to collect and the amount of specimen they
would set as a goal, as well as being allowed to choose their own methods to
manage their biobanks (autonomy). Therefore, some biobanks collected
resources that were easy to collect and the resources needed by researchers
were not strategically collected. In addition, there was also a low distribution
rate to researchers outside of hospitals, who do not have as much access to
specimens and cases as those in hospitals. There were also many cases in which
researchers were not aware of the KBP, and the distribution processes were not
set up to be convenient to the demands of researchers.
Accordingly, the second phase of the KBP will be focused on increasing the
integration and cooperation between the biobanks within the network. The KBP
plans to set goals for the strategic collection of the needed human bioresources.
Although the main principle of the first phase was to establish infrastructure and
resource collection, the key objective of the second phase is the efficient
utilization of gathered resources. In order to fully utilize the gathered resources
in an efficient way, distribution systems and policies must be improved. Vitali-
zation of distribution, securing of high-value resource and related clinical and
laboratory information, international standardization of resource management
systems, and establishment of a virtuous cycle between research and develop-
ment (R&D) and biobanks are the four main strategies. Based on these strategies,
12 related objectives have been set and are planned to be executed.1. Introduction
1.1. Importance of a biobank as an
infrastructure for biomedical research to
realize personalized medicine
Recently, there has been a shift in patient treatment,
i.e., a shift from treating patients after contracting
diseases to personalized medicine, in which diseases
are prevented and treated according to individual
genetic differences. Following the trend, biobanks have
been stressed as an important basic infrastructure for
biomedical research and the way to open up a new era of
personalized medicine. In the past 10 years, there have
been continuous researches and studies in Korea on
various related topics, such as relationships between
genes and diseases, health behaviors, and interactions
with environmental factors. Such researches have been
carried out in large scales through research consortiums,
and various cohorts have been established to study the
incidence and causes of chronic diseases. Accordingly,
it has become necessary to establish a biobank to collect
and supply large amounts of samples to researchers or
effectively manage the collected specimens. In addition,
many medical professionals have come to realize that
biobank and its biobank network would be essential to
support specified researches pertaining to the analytic
study of Korean genetic material, especially because
such research is needed to make personalized medicine
in Korea. The biobank network would also collect high-quality human biospecimens and related clinical,
epidemiological, and laboratory information, making
such information more accessible for researchers.
1.2. Background of the Korea Biobank Project
Over the recent decades, the Korean government has
increasingly noticed the growing importance of bio-
specimens. The Ministry of Education and Science
Technology, the Ministry of Environment, and the
Ministry of Health and Welfare have been working
together to build biobanks to catch up with the
government’s intent. In 1995, the Ministry of Education
and Science Technology established the Korea National
Research Resource Centers for collecting various bio-
resources including specimens from plants and animals.
Five of the 36 research centers that are part of the
network collect human biospecimens. However, the
scale and variety of the collections were small because
collections were made on an individual research project
level. The Ministry of Environment established bio-
banks through cohorts to study the effect of harmful
environmental substances on the human body, but
their samples were limited to specimens needed for
researching environmentally induced diseases. There-
fore, there was a necessity to establish a biobank that is
centered on hospitals, and not just on individual
research-level studies, especially within general hospi-
tals run by universities. In 2008, the Ministry of Health
and Welfare started the Korea Biobank Project (KBP)
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university-affiliated general hospitals as well as creating
a network among these biobanks [1,2].
1.3. Changes in biobanks within and outside of
Korea
Over the last two decades, many biobanks and inter-
national collaborations have been installed to obtain the
needed critical mass of a certain of biospecimen to
commence biomedical researches. Especially the number
of population biobanks and projects (i.e. UK biobank (3),
Estonian Genome Project (4), Chinese Kadoorie study (5)
and others) has significantly increased on the completion
of theHumanGenome Project. The international trend has
also recently spread to developing countries (Table 1) [3].
InMarch 2009, the TimeMagazine chose biobanks as one
of the “10 Ideas Changing the World Right Now,”
stressing the biobank’s prospective influence on future
significance in medicine [4]. The UK biobank has secured
biospecimens from 500,000 people between 2006 and
2010, and hasmade it official that theywould be supplying
their specimens to researchers starting from March 2012
[5,6]. Over the years, many biobanks have been estab-
lished and aremoving froma phase of sample collection to
provide their samples for researches. It can be predicted
that biobanks will continue to greatly influence biomed-
ical research and medical treatment in the future.
In Korea, The Bioethics and Safety Act has been
completely revised to reinforce research ethics within
the country and will be effective in 2013. Based on the
newly revised law, it can be predicted that the number of
biobanks within university-affiliated hospitals will grow.
Laws pertaining to bioethics and safety encourage bio-
banks to reinforce ethical use of biospecimens. In
addition, the law underlines biobanks’ responsibility to
obtain informed consent from donors and oversight by
institutional review boards. The law also encourages
individual researchers to deposit and use biospecimens
at any biobanks instead of collecting their own samples.
Biobanks are also included as obligatory criteria in
the “research-centered hospital” program initiated by the
Ministry of Health and Welfare for enhancing clinical
researches at hospitals. In order for hospitals to qualify
as a ministry-listed “research-centered hospital” and
receive financial support from the government body forTable 1. Biobanks with sample sizes 200,000 (2010)
Name of biobank Size (age grou
UK Biobank 500,000+(40-69 y
Estonian Genome Project w1 million
Icelandic deCode Biobank w250,000
Kadoorie Study of Chronic Diseases in China 500,000 (35-74 y
The Mexico City Prospective Study 160,000 (35+ yr)
The Indian National Biobank w2-3 million (18
Note. Sgaier SK, et al. (2007) Biobanks in Developing Countries: Needs andresearches, they must have a biobank. This program is
another reason the number of biobanks is likely to
increase in Korea in the coming years.
Until now, the biospecimens collected by the KBP
are provided to researchers free of charge, but do not
provide samples for industrial use. However, recently,
many pharmaceutical companies and venture enterprises
have begun to request distribution of samples for their
own research. In the future, it looks likely that the
regulations will change to also provide samples to
industries, though systemic changes, such as charging
fees for the samples, will be necessary.2. Major Achievements and Limitations of
the First Phase of the KBP
2.1. Main achievements
The KBP was initiated in 2008 to cooperate with the
National Biobank of Korea and eight biobanks of
university-affiliated hospitals. The number of registered
biobanks in the network has increased every year, and in
2012, there were 17 biobanks of university-affiliated
hospitals, in addition to the National Biobank of Korea,
as part of the network (Figure 1). The biobanks that are
within the Korea Biobank Network (KBN) use the
single Biobank Information Management System
(BIMS) to manage information on biospecimens they
collect (Figure 2). The objective of the first phase of the
KBP was to collect specimens from 500,000 people and
to provide samples for 500 or more research projects [1].
This objective was achieved in 2012. Specimens from
300,000 people have been collected by population-based
cohorts established by the government, and the
remaining specimens have been collected from 200,000
people who came to the university-affiliated hospitals
[7]. In April 2012, the National Biobank of Korea
opened its dedicated building, which means that a better
infrastructure has been established for stable storage,
management, and distribution of biospecimens for
related researches (Figure 3) [8]. It has enough space to
store biospecimens from 1,000,000 people (i.e.,
approximately 30 million vials). The National Biobank
of Korea has been constructed to allow for renovation
and expansion. Another achievement of the KBP is thatp) Start-up cost Chronic Disease Infectious Disease
r) $120 million Yes No
$2.5 million Yes No
$212 million Yes No
r) $22 million Yes Some
Not available Yes Some
+ yr) $20-30 million Yes Yes
Feasibility. Science 318:1074e5 [3].
Figure 1. Nationwide distribution of biobanks participating in the Korea Biobank Project in 2012. KCDC Z Korea Centers for
Disease Control and Prevention; NUH Z National University Hospital.
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have a clear understanding as well as technical skills
necessary for the successful management of biobanks.
2.2. Limitations
The first phase just focused on resource collection,
and therefore there were not many distribution routes toFigure 2. A screen shot of the Biobanresearchers. In particular, the project was not able to
meet the demand of researchers outside of the project.
So far, samples were provided to approximately 600
research projects, but the rate of distribution to
researchers outside of the university hospitals who have
less access to biospecimens is comparatively less (only
one in three researchers had access and utilizedk Information Management System.
Figure 3. A bird’s-eye view of the newly constructed National Biobank of Korea and its structure.
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sary to increase the rate of distributions to such
researchers.
Another issue is that there is not enough related
clinical and laboratory data on specimens within affiliated
biobanks. A few of the biobanks use the electronic
medical record system (EMRS) to synchronize their
clinical databases with the BIMS database, but most of
the biobanks are not automatically linked to the elec-
tronic medical record, and therefore, it is difficult to
compile comprehensive clinical information. In addition,
during the first phase, the KBP respected the autonomy of
individual biobanks, allowing them to collect whatever
specimens and data they had wished for, but from now on
it may be more effective for the government to select and
rate the most needed specimens and set goals for better
coordinated specimen collection.
In the first phase, the KBP secured budgets to
purchase storage facilities such as deep freezers and
liquid nitrogen tanks as well as cover labor costs for the
biobank personnel. However, research funding for using
the collected specimens was scarce, and so it was not
possible to put the gathered samples to use in researches.
High-quality specimen can be collected much more
efficiently when collected through research projects,
which is why systemization of virtuous cycle between
research projects and the biobanks would be beneficial
for both parties. Specimens collected through research
projects can be stored in biobanks, and therefore be
available for further projects; research results can alsodisclose useful information on the provided bio-
specimens, which can then be used as secondary
resources.
Another problem is that even though there have been
various publicity promotions for the KBP to researchers,
awareness of the KBP and the KBN is relatively low.
According to an online survey on the demand for bio-
resources in research (2012), only approximately 7% of
the participating researchers responded that they had
experience using the KBN website (http://kbn.cdc.go.
kr/) [9]. Furthermore, 65.5% of the participants were
not even aware that they could acquire bioresources
through the KBP-affiliated biobanks [9]. This highlights
that there must be constant publicity for the KBN.3. Vision and Mission of the Second Phase
of the KBP
The vision and mission will be the same as set in the
first phase of the KBP and are as follows:
 Vision: “Realizing biobanks for a healthy future
society”
 Mission: “Promoting public health through enhancing
biomedical researches”
 Objective: “Distributing biospecimens to more than
1000 studies”
Based on the discussions, four strategies and 12objectives were identified (Figure 4).
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Phase of the KBP
4.1. Strategy 1: To establish a demand-centered
distribution system
4.1.1. Objective 1: To establish a one-stop
distribution system
The KBN website (http://kbn.cdc.go.kr) provides its
introduction, a search engine functionality, and a list of
available biospecimens at the moment. However, the
search function is not sufficient enough to get diverse
information. Regarding the biospecimens stocked in the
National Biobank of Korea, there are approximately 2000
variables of data that are linked to each specimen and it is
possible to search through them by filling out certain
required fields. However, it still needs to improve its
efficient search function for researchers. Data gathered
from the 17 regional biobanks participating in the KBN
are not easy to standardize, and the BIMS has only 18
variables filled out on the form, making a search through
them almost insufficient for researchers.
Furthermore, samples are distributed at both the
National Biobank of Korea and the 17 regional bio-
banks. Researchers in need of specimens must find
a biobank, contact the bank in person, and request to
receive it. During the second phase, one of the objec-
tives of the KBP is to set up an online one-stop distri-
bution system that would allow researchers to search for
resources, request, and receive specimen as well as
upload the results of their research, all through a single
system. In order to achieve this, each biobank in theFigure 4. Framework of the strategic pnetwork must compile standardized data on their bio-
specimens according to the condition or disease the
specimens pertain to. In addition, a center for bio-
specimen distribution must be set up to manage opera-
tion, coordinate requests, and connect researchers to the
biobank, so as to allow them to get what they need.
4.1.1.1. Execution plan
 Develop an online portal for a demand-centered
distribution: (1) improving database creation and
search function through standardization of biobank
specimen information; and (2) developing an online
system to register requests for specimen distribution,
view distribution confirmation/denial status of the
requested specimen, and upload research results.
 Create distribution centers to better coordinate
distributions of biospecimens by the 17 affiliated
biobanks: (1) developing a single unified distribution
system aided by professional coordinators with whom
researchers can consult; and (2) developing objective
distribution policies and a standardized distribution
manual for a more fair and synchronized process.
4.1.2. Objective 2: To revise process and regulate
distribution of biospecimens
At present, the KBP does not supply specimens to the
industrial sector, but there have been requests for
specimen distributions from various industries. Thus, in
the second phase, the KBP will begin distribution of
biospecimens to pharmaceutical companies and medicallan for the second phase of the KBP.
Second Phase (2013e2015) of the Korea Biobank Project 113industries. Because the amount of specimens requested
by industries is relatively larger than other research
projects and there are a lot more requests in general, it is
difficult to distribute specimens to industries free of
charge. Therefore, the policy for industrial distributions
should include a fee.
It is also necessary for them to be a quicker process
so as to aid in decision making of distributing bio-
specimens. Currently, there is a monthly committee
meeting that deals with matters related to its distribu-
tion, but some less significant matters, such as simple
period extensions at the time of research, use of
distributed resources, or requests for additional data
should be judged in a faster and simpler process. It will
be necessary to introduce a simpler and faster working
judging panel for less serious matters. Although bio-
specimens are only distributed to funded research
projects at this time, there is an increasing demand to
approve distribution of biospecimens to pilot studies that
are without research funding.4.1.2.1. Execution plan
 Improve policy for simplification of the distribution
process: introduction of a simpler and faster working
judging panel for less serious matters regarding the
distribution of biospecimens.
 Promote policy for a larger distribution base: (1)
extending the scope of distribution to pilot studies
without research funding; and (2) enlargement of
sectors including pharmaceutical and medical
companies.
4.1.3. Objective 3: To expand types of
biospecimen distribution
The National Biobank of Korea has stored speci-
mens including DNA, plasma, serum, urine, whole
blood, lymphoblastoid cell lines (LCLs), etc. of each
donor. Currently, only DNAs are distributed. Because
the DNA for distribution purpose is mounted on an
automated working bank, so the DNA can be easily
distributed. The other reason is that the policy decision
for distribution of plasma, serum, urine, or LCLs has
not yet been made. By contrast, many researchers are
requesting that these resources are distributed exten-
sively, and therefore a plan to allow such distributions
must be formulated.4.1.3.1. Execution plan
 Expand distribution of human biospecimen items
from only DNA to plasma, serum, urine, and LCLs:
(1) establishment of plans to distribute bio-
specimens other than DNA such as serum, plasma,
urine, and LCLs; and (2) program for automaticworking of serving information on plasma, serum,
urine, etc.4.2. Strategy 2: To secure and utilize high-value
bioresources
4.2.1. Objective 1: To produce a panel of high-
quality biospecimens
The National Biobank of Korea and regional bio-
banks participating in the KBN prepare data based on
a request by a researcher and provide information he or
she requested. In addition, a panel, immediately possible
to use, can increase the utility of bioresources. Some
researchers requested panels related to biospecimens
and information analyzed with its previous use. For
example, in the case of distribution of LCL, some
researchers want to get preanalyzed genotype data
together. Accordingly, it needs to produce a panel
connected to supplementary data having clinical,
epidemiological, and genetic information prior to
providing them. It is also possible to produce a panel of
DNA, plasma, serum, urine, etc. from a population
considered “healthy.” Furthermore, biospecimen panels
of case and control of target diseases in cohorts will be
utilized efficiently. If a panel is produced by sets of
clinical information on a whole set of bio-
specimensdserum, plasma, urine, cancer tissue, and
DNAdof a patient, the quality of the biospecimens will
be improved. Therefore, there is a need to survey the
demand of researchers, and then the National Biobank
of Korea can provide state-of-the-art information to
researchers.4.2.1.1. Execution plan
 Utilize bioresources through a production of
resource panel: (1) production of biospecimen
panels having both personal information, such as
tissue, plasma, serum, urine, and DNA, and clinical
information; and (2) production of a panel in the
level of cohort including target diseases or condi-
tions between patients and control group.4.2.2. Objective 2: To establish disease-collection
system of specific biospecimens
During the first phase of the KBP, the collection of
biospecimens in regional biobanks was centered on
tissues, including solid cancer tissues, and collection of
biospecimens from patients with highly prevalent
diseases; however, there is not enough collection of
tissues from patients with rare diseases, which indi-
vidual doctors may find difficult to collect on their own.
Such specimens must be collected through research
projects or by establishing a network of medical doctors
who specifically work with those diseases. In addition,
certain biobanks should be registered as specialized
114 O. Park, et albanks to secure specimens that are usually difficult to
collect in each hospital.
4.2.2.1. Execution plan
 Establish systemic methods to collect biospecimens
related to rare diseases: (1) selection, categorization,
and collection of specimens obtained from patients
with rare diseases; and (2) establishing a network
of medical professionals working with rare diseases
or collecting rare-disease bioresources through
research projects.
 Select and run specialized biobanks: establishing
specialized biobanks focusing on the collection of
certain bioresources that are difficult to find.
4.2.3. Objective 3: To revise BIMS for disease
collection of specific biospecimens
The current BIMS is developed to generate ID
numbers for each sample and then ask for information
related to the sample to be inserted. However, the system
needs to be improved to make it easier for long-term
follow-ups on donor patients, whose information has
been collected at periodic intervals, including informa-
tion needed to fulfill Objective 1 and Objective 2,
described previously. The BIMS must be made flexible,
which allows for the customization of necessary clinical
information according to the disease, and to allow for
a long-term informational follow-up on patients.
4.2.3.1. Execution plan
 Improve the functions of BIMS: (1) enhancing the
function of BIMS to be able to insert and manage
information on resources will that need long-term
tracking, information on specialized biobanks and
their resources, as well as specific information on
resources for certain diseases; and (2) development
of a program to automatically synchronize clinical
information of EMRS with BIMS.
4.3. Strategy 3: To advance a resource
management system
4.3.1. Objective 1: To develop and operate
a standardized resource management
In the case of biobanks within the KBN, each biobank
creates and uses their own standard operating procedure
(SOP) according to the policy formulated by the KBN.
However, biobanks have been asserting the need for
developing a common SOP that biobanks can refer to.
Although efforts have been made to develop a SOP, this
task has not been completely fulfilled. In the future, there
should be development and application of a common SOP
that comprehensively compiles research results conducted
up until now, as well as collects and stores resources,
performs quality control, adheres to safety regulations, andsecures personal information for privacy protection. In
addition, international standards on resource management
should be introduced [e.g., the International Society for
Biological and Environmental Repositories’ (ISBER)
StandardPre-analyticalCode (SPREC)] in order to provide
information related to the processes of resource collection,
storage, and quality control.
4.3.1.1. Execution plan
 Develop and apply the SOP: (1) introduction of an
SOP according to the type of specimens and stage of
management; (2) assigning SPREC to the National
Biobank of Korea and other biobanks according to
resource management and BIMS application; and
(3) enhancement of training program for workers in
regional biobanks on SOP.
4.3.2. Objective 2: To introduce a biobank
certification policy
At present, the KBN-affiliated biobanks submit
a yearly plan as well as a report of project results. The
results, which are reviewed and evaluated, are used to
decide the amount of government funding needed for the
biobanks. However, the current evaluation methods are
usually based on the amount of resources collected, the
degree to which the biobanks are managed ethically, and
the manner in which the biobanks are run. At this point,
there are no direct assessments on actual resource
collection, storage, and quality control. Evaluation is
mainly based on the written reports submitted by the
biobanks. Accordingly, an external quality control
program should be introduced, and the quality of the
biobank should be improved through a biobank certifi-
cation process, which is evaluated through a peer review
process. This certification process should later be
extended to all the biobanks within the country, including
those that are not part of the KBN.
4.3.2.1. Execution plan
 Establish external quality control policy: (1) estab-
lishment of a quality control committee and an external
quality control program; (2) evaluating quality
controls at individual biobanks; and (3) proficiency
testing for biobanks regarding quality control.
 Execute biobank certification policy: (1) biobank
certification policy evaluating the skill of the
professional, operation of biobanks, privacy
protection of donors, etc. should be implemented.
4.3.3. Objective 3: To strengthen collaboration
with biobanks around the world
Since the 1990s, various countries around the world
have been establishing large-scale biobanks. Approxi-
mately 70% of the biobanks are stand-alone, and 30%
Second Phase (2013e2015) of the Korea Biobank Project 115are partnership banks. Internationally, many different
biobanks are being established and there has been an
increase in the number of cooperative research projects
between biobanks across nations. At present, there are
various standardizations such as the ISBER, Public
Population Program in Genomics, and Biobanking and
Biomolecular Resources Research Infrastructure for
cooperative research projects. For the KBN to grow as
an international biobank, there must be cooperation with
other international biobanks.
4.3.3.1. Execution plan
 Encourage publicity for theKBPand efforts to increase
international credit: (1) active publicity for the KBP;
and (2) developing promotional materials (English
leaflets, English website, or promotional videos).
 Collaborate foreign biobanks through a memorandum
of understanding: (1) researcher exchange training;
and (2) research cooperation, joint symposiums, etc.
4.4. Strategy 4: To systemize R&D biobanks
virtuous cycle
4.4.1. Objective 1: To plan R&D-based human
bioresources collection and utilization
In the first phase of the KBP, biobanks focused on
securing basic facilities, such as purchasing resource
storage equipment as well as securing labor costs and
management costs. Although research and development
R&D funds for research that utilize the biobank
resources were sought, they were not approved, which is
why the collected bioresources could not be fully
utilized. However, such funds are necessary because
more high-quality resources are secured through
research, which increases the interest and participation
in research among clinicians that allows for the gath-
ering of high-quality resources with more information.
Therefore, in the second phase, more researches that
better utilize the current specimens will be planned, and
more efforts will be made to secure necessary funding.
In addition, there will be more R&D projects that
support clinicians, so that it will be possible to gather
resources with more information. For example, the
National Biobank of Korea has collected and stored
specimens from Korea National Health and Nutrition
Examination Survey as well as from various cohorts to
study chronic diseases, but there are not enough research
funds for the researches to use these bioresources.
Therefore, it is necessary to find or develop more
research projects and funds for the research projects in
which these resources can be utilized.
4.4.1.1. Execution plan
 Plan and execute R&D research projects to better
utilize specimens (bioresources) stored in the KBN:
(1) developing a plan for research projects that canmake use of the regional biobanks’ specimens; (2)
identifying funding source and subsequently
securing funds for research projects that can make
use of the specimens in the National Biobank of
Korea, obtained from various cohorts and the Korea
National Health and Nutrition Examination Survey;
and (3) creation of high-value resources through
attaching related research results to already existing
specimens by making submission of research results
using distributed specimens mandatory.
 Secure bioresources through planned R&D projects:
finding and funding planned R&D projects to collect
biospecimens with information.
4.4.2. Objective 2: To co-plan and co-execute
national-level research projects
There are many national-level research projects using
bioresources, but there is no official integration system
that connects these national projects to the KBN. Large-
scale national researches usually have their own systems
of acquiring resources, so it may help to co-plan such
research projects and use the bioresources from the KBN
to make way for prospective biospecimen collection.
4.4.2.1. Execution plan
 Establish a collaborative system with current
national-level research projects: (1) collaborate with
the National Research Foundation of Korea and the
Korea Health Industry Development Institute to plan
research projects that use bioresources in the KBN;
and (2) establishing prospective collection and
provision of biospecimens to national-level research
projects through the KBN.
4.4.3. Objective 3: To establish and execute public
relations centered on possible consumers
Researchers are both the consumers and providers of
the bioresources. However, because many researchers’
awareness and interest in the KBP and the KBN are
relatively low, collection and distribution of resources
are still not completely established. Therefore, it is
necessary to raise more awareness about the project and
encourage participation and resource utilization. In
addition, publicity directed toward the public is neces-
sary to raise awareness and educate on the need for
donating bioresources.
4.4.3.1. Execution plan
 Establish advisory board for publicity: (1) estab-
lishment and operation of advisory board for
publicity and systemic publicity schemes for the
maximization of efficacy.
 Enhancement of publicity for experts: (1) operation
of publicity booths at academic conferences and
116 O. Park, et alpresentation of research results related to biobanks;
and (2) publicity through related portals, such as the
Centers for Disease Control and Prevention
website.
 Develop a publicity method directed toward the public
to encourage donations: publication and distribution of
promotional materials aimed at patients visiting
hospitals.
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